1. Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer.
- Author
-
Shi Y, Fu Y, Zhang X, Zhao G, Yao Y, Guo Y, Ma G, Bai S, and Li H
- Subjects
- Animals, Apoptosis drug effects, Apoptosis immunology, Cell Cycle Checkpoints drug effects, Cell Cycle Checkpoints immunology, Cell Line, Tumor, Cell Proliferation drug effects, Colonic Neoplasms metabolism, Female, G1 Phase drug effects, G1 Phase immunology, Gene Expression Regulation, Neoplastic immunology, Histones metabolism, Immunotherapy methods, Ligands, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Resting Phase, Cell Cycle drug effects, Resting Phase, Cell Cycle immunology, T-Lymphocytes drug effects, T-Lymphocytes immunology, Transcription Factors metabolism, Tumor Microenvironment drug effects, Tumor Microenvironment immunology, B7-H1 Antigen antagonists & inhibitors, Colonic Neoplasms drug therapy, Colonic Neoplasms immunology, Depsipeptides pharmacology, Gene Expression Regulation, Neoplastic drug effects, Immunity, Cellular drug effects
- Abstract
Romidepsin (FK228), a histone deacetylase inhibitor (HDACi), has anti-tumor effects against several types of solid tumors. Studies have suggested that HDACi could upregulate PD-L1 expression in tumor cells and change the state of anti-tumor immune responses in vivo. However, the influence of enhanced PD-L1 expression in tumor cells induced by romidepsin on anti-tumor immune responses is still under debate. So, the purpose of this study was to explore the anti-tumor effects and influence on immune responses of romidepsin in colon cancer. The results indicated that romidepsin inhibited proliferation, induced G0/G1 cell cycle arrest and increased apoptosis in CT26 and MC38 cells. Romidepsin treatment increased PD-L1 expression in vivo and in vitro via increasing the acetylation levels of histones H3 and H4 and regulating the transcription factor BRD4. In subcutaneous transplant tumor mice and colitis-associated cancer (CAC) mice, romidepsin increased the percentage of FOXP3+ regulatory T cells (Tregs), decreased the ratio of Th1/Th2 cells and the percentage of IFN-γ+ CD8+ T cells in the peripheral blood and the tumor microenvironment. Upon combination with an anti-PD-1 antibody, the anti-tumor effects of romidepsin were enhanced and the influence on CD4+ and CD8+ T cells was partially reversed. Therefore, the combination of romidepsin and anti-PD-1 immunotherapy provides a more potential treatment for colon cancer.
- Published
- 2021
- Full Text
- View/download PDF